In Massachusetts, TEPHA Inc. completed a buy-out of its royalty obligation to Metabolix, Inc., its former licensor and parent company. TEPHA develops implantable medical devices based on biomaterials, including a biologic polymer called poly4hydroxybutyrate (P4HB) which is made through a fermentation process. Andrew Joiner, President and CEO of Tepha, told PR Newsire “The buy-out of our royalty obligation in conjunction with Metabolix was financially advantageous for both companies. Specifically for Tepha, the cash flow from our savings will help finance the continued development of our core technology as well as pre-clinical and clinical testing of new applications.” TEPHA plans on using its P4HB-based fibers to expand into collagen, antibiotic coatings and non-woven materials in new markets.
Latest article
From larvae to laundry: Sasol introduces insect oil-based surfactant
In Houston, Sasol has introduced a surfactant made from oil obtained from black soldier fly larvae.
Trade named LIVINEX IO 7, the insect-based surfactant meets...
Fungi fix: Dutch designer Dierkx shows mycelium can convert waste plastic into protein bars
In the Netherlands, designer Odette Dierkx has envisioned a new concept for producing protein bars: dried mycelium that has been fed waste plastics.
Dubbed...
Green toilet clean: Henkel taps LyondellBasell for biobased toilet cleaner packaging
In Germany, cleaning products giant Henkel is using biobased plastic from Houston’s LyondellBasell in its toilet cleaner packaging.
The packaging will specifically use LyondellBasell’s...